POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.
Did Not Advance

House Bill 944 Extends Bans on Insurance Step-Therapy Protocols for Advanced Cancer Drugs

Original title: Advanced, metastatic cancer; extend and codify repealer on prohibition against health plans requiring step therapy before covering certain drugs to treat.

Last action · February 3, 2026: 02/03 (H) Died In CommitteeSponsor: Fred Shanks

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

What This Bill Proposed

House Bill 944 reenacts and extends restrictions preventing health benefit plans from requiring step-therapy or s before covering certain drugs, setting a new repeal date of July 1, 2029.

Why it matters

Extends insurance regulations governing whether cancer patients must try alternative medications before receiving prescribed treatments, affecting coverage timelines and clinical override processes.

Who It Would Have Affected

Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.

Directly affected

Patients with advanced, metastatic cancer

Enrollees receive continued protection from being required to try and fail alternative drugs before health plans cover prescribed treatments for advanced cancer.

Directly affected

Insurers

Health benefit plan providers must continue to comply with restrictions on step-therapy protocols and maintain override processes through July 1, 2029.

Directly affected

Prescribing practitioners

Doctors and health care providers retain access to established override processes to request exceptions to insurer medication restrictions.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

Does this bill apply to all prescription drugs?
No, it applies only to FDA-approved prescription drugs used to treat and associated conditions that are consistent with best practices and supported by peer-reviewed, evidence-based literature.
What is the new expiration date for these insurance restrictions?
The provisions are extended to stand repealed on July 1, 2029.
Can a doctor override an insurer's step-therapy requirement?
Yes, prescribing practitioners have access to a clear and convenient process to request an override based on clinical evidence, such as when preferred treatments have been or are likely to be ineffective or harmful.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

This bill did not become law - Died in committee.

Procedural history

2 actions
  1. Feb 3, 2026House
    02/03 (H) Died In Committee
  2. Jan 16, 2026HouseCommittee
    01/16 (H) Referred To Public Health and Human Services

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Connected Entities

Fred Shanks, United States Food and Drug Administration
PersonFred Shanks“Representative who introduced House Bill 944”Map →
OrganizationUnited States Food and Drug Administration“Approves prescription drugs required for coverage under the bill”Map →

Sources

Open source document

billstatus.ls.state.ms.us

Analysis Score

0–100
  • Significance20
    Lowered because this bill did not pass (its text scored 60)
  • Controversy30
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz20
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record